Latest news from ISOLPHARM
New publications for the ISOLPHARM laser group
We are happy to announce the publication of two new papers regarding the work of our laser group. The first one, entitled “Laser photo-ionization study of natAg using opto-galvanic signal[…]
Read more
ISOLPHARM laser group at ICFDT6
The SPES-ISOLPHARM laser group took part to the 6th International Conference Frontiers in Diagnostic Technologies (ICFDT6), organized by ENEA and INFN in Frascati (Italy) from 19th to 21st October 2022.[…]
Read more
First deposition using IRIS
During the last week, the collaboration has successfully tested the IRIS (ISOLPHARM Radionuclide Implantation Station) device. The system was coupled and aligned with the SPES Offline beamline in order to[…]
Read moreA Large Collaboration Between Universities and Research Centers
The ISOLPHARM Project was born from the collaboration between the Departments of Pharmaceutical and Pharmacological, Department of Chemical Sciences of the University of Padova and the Legnaro National Laboratories (LNL) of the National Institute of Nuclear Physics (INFN) where the Selective Production of Exotic Specie (SPES) project in under development. By means, of Isotope Separation On-Line technique both traditional and innovative radioisotopes will be produced with high-specific activity, going beyond the state-of-art of the radioisotope production.
Read more
Strengths and key features
The key features of ISOLPHARM are: a) the presence of a strong local collaboration between INFN-LNL, INFN-PD, INFN-PV, TIFPA, UNIPD and UNIBS in many fields of research, ranging from the production of the RIBs to the employment of the radionuclides. b) the ISOL technique, which can easily provide high specific activity radionuclides. c) the INFN patent, which proves the innovation and excellence of the project. d) the low environmental and social impact, since nuclear reactors are not used for the provision of the radionuclides, which traditionally may be obtained irradiating massive amount of materials, that lately become tons of nuclear wastes.
Advantages
VERSATILITY
Production of a large set of radionuclides carrier-free and with large radionuclide purity
INNOVATIVITY
Many unconventional radioisotopes (short T 1/2) difficult to produce with traditional techniques
FLEXIBILITY
On-line mass selection by tuning the separator; easy production of different radionuclides
GREEN
Low production of radioative waste material
2023-2025 Project
ISOLPHARM_ADMIRAL
The future for radiopharmaceutical production at ISOLPHARM
